Deutsche Bank Downgrades ACADIA Pharmaceuticals to Hold, Announces $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
Deutsche Bank analyst Neena Bitritto-Garg has downgraded ACADIA Pharmaceuticals (ACAD) from Buy to Hold and set a price target of $25.
December 14, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
ACADIA Pharmaceuticals was downgraded by Deutsche Bank from Buy to Hold with a price target of $25.
Downgrades by major banks can lead to a neutral short-term impact as the market absorbs the news. The price target of $25 suggests a potential upside or stabilization, mitigating negative sentiment.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100